TriangleNCT02793544 · OUTCOME
Cumulative Incidence of Relapse/Progression
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 90% Confidence Interval
- Time frame
- 180 days and 365 days post-transplant
What was measured
Defined by either morphological, cytogenetic/molecular or radiological evidence of disease consistent with pre-HCT features. A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.
Groups in this outcome
Myeloablative Conditioning (MAC)
Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan
Reduced Intensity Conditioning (RIC)
Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation
| Group | Source count |
|---|---|
| Myeloablative Conditioning (MAC) | 40 |
| Reduced Intensity Conditioning (RIC) | 40 |
Reported measurements
180 days
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Myeloablative Conditioning (MAC) | 22.6 | Not reported | 12.6 | 34.5 | Not reported |
| Reduced Intensity Conditioning (RIC) | 20 | Not reported | 10.6 | 31.5 | Not reported |
365 days
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Myeloablative Conditioning (MAC) | 30.4 | Not reported | 18.9 | 43.2 | Not reported |
| Reduced Intensity Conditioning (RIC) | 22.5 | Not reported | 12.6 | 34.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 12.6
- upper Limit
- 34.5
- value
- 22.6
- group Id
- OG001
- lower Limit
- 10.6
- upper Limit
- 31.5
- value
- 20
- title
- 180 days
- categories
- measurements
- group Id
- OG000
- lower Limit
- 18.9
- upper Limit
- 43.2
- value
- 30.4
- group Id
- OG001
- lower Limit
- 12.6
- upper Limit
- 34.3
- value
- 22.5
- title
- 365 days
- denoms
- counts
- group Id
- OG000
- value
- 40
- group Id
- OG001
- value
- 40
- units
- Participants
- description
- Defined by either morphological, cytogenetic/molecular or radiological evidence of disease consistent with pre-HCT features. A cumulative incidence will be computed along with a 90% CI. Death from any cause. The time to this event is the time from HCT to death, loss to follow-up, or end of study (whichever comes first). The overall survival probability and 90% CI will be calculated by the Kaplan Meier product limit estimator.
- dispersion Type
- 90% Confidence Interval
- groups
- description
- Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan
- id
- OG000
- title
- Myeloablative Conditioning (MAC)
- description
- Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation
- id
- OG001
- title
- Reduced Intensity Conditioning (RIC)
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 180 days and 365 days post-transplant
- title
- Cumulative Incidence of Relapse/Progression
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice